Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Elecoglipron Test formulation 1 Dose B, Active IMP
Elecoglipron · 9 trials · 8 indications
Time to first event of the composite of: * CV death * HHF * Urgent HF visit
Time to the first occurrence of any component of this composite: * ≥ 50% sustained decline in eGFR * ESKD defined as sustained eGFR \< 10 mL/min/1.73 m2, or Chronic dialysis treatment, or Receiving a renal transplant * All-cause mortality
Percent change from baseline to Week 52 in body weight.
Achieved at least 5% body weight loss from baseline at Week 52.
Summary statistics
Percent change from baseline to Week 72 in body weight
| Arm | Type | Description |
|---|---|---|
| Elecoglipron | EXPERIMENTAL | Elecoglipron tablet once daily |
| Placebo | ACTIVE_COMPARATOR | Placebo matching Elecoglipron tablet once daily |
| Arm 1 - Dose 1 | EXPERIMENTAL | Active IMP |
| Arm 2 - Dose 2 | EXPERIMENTAL | Active IMP |
| Arm 3 - Placebo | PLACEBO_COMPARATOR | Placebo matching elecoglipron |
| Elecoglipron dose level 1 | EXPERIMENTAL | Participants will receive elecoglipron at dose level 1 administered orally once daily. |
| Elecoglipron dose level 2 | EXPERIMENTAL | Participants will receive elecoglipron at dose level 2 administered orally once daily. |
| Elecoglipron dose level 1 + dapagliflozin-matched placebo | EXPERIMENTAL | Participants will receive elecoglipron at dose level 1 and dapagliflozin-matched placebo, administered orally once daily. |
| Elecoglipron dose level 2 + dapagliflozin-matched placebo | EXPERIMENTAL | Participants will receive elecoglipron at dose level 2 and dapagliflozin-matched placebo, administered orally once daily. |
| Elecoglipron (one of the studied dose levels) + dapagliflozin | EXPERIMENTAL | Participants will receive elecoglipron at one of the study dose levels in combination with dapagliflozin, administered orally once daily. |
| Elecoglipron-matched placebo + dapagliflozin-matched placebo | PLACEBO_COMPARATOR | Participants will receive elecoglipron-matched placebo and dapagliflozin-matched placebo, administered orally once daily. |
| Elecoglipron dose level 1 + dapagliflozin | EXPERIMENTAL | Participants will receive elecoglipron at dose level 1 and dapagliflozin, administered orally once daily. |
| Elecoglipron dose level 2 + dapagliflozin | EXPERIMENTAL | Participants will receive elecoglipron at dose level 2 and dapagliflozin, administered orally once daily. |
| Elecoglipron-matched placebo + dapagliflozin | ACTIVE_COMPARATOR | Participants will receive elecoglipron-matched placebo + dapagliflozin, administered orally once daily. |
| Semaglutide | ACTIVE_COMPARATOR | Participants will receive semaglutide dose XX mg administered orally once daily. |
| Name | Type | Description |
|---|---|---|
| Elecoglipron | DRUG | Elecoglipron tablet |
| Placebo | DRUG | Placebo tablet |
| Dapagliflozin | DRUG | Dapagliflozin administered orally once daily. |
| Elecoglipron-matched placebo | DRUG | A placebo matching elecoglipron, administered orally once daily. |
| Dapagliflozin-matched placebo | DRUG | A placebo matching dapagliflozin, administered orally once daily. |
| Semaglutide | DRUG | Semaglutide is administered orally once daily. |
Inclusion Criteria: * Left ventricular ejection fraction (LVEF) of \> 40% within 12 months prior to screening. * Structural heart disease evidence. * HF diagnosed with New York Heart Association (NYHA) Class II-IV at the time of screening. Exclusion Criteria: * BMI \<25 kg/m² at screening. * Diab...
Top 20 of 28 competitors
Elecoglipron is an investigational small molecule developed by AstraZeneca PLC (ticker AZN). It is being studied in Phase 3 clinical trials for chronic kidney disease, heart failure with preserved ejection fraction (HFpEF), obesity, type 2 diabetes mellitus, and weight management. It is not yet approved and remains in clinical development.
Elecoglipron is being evaluated for chronic kidney disease, heart failure with preserved ejection fraction (HFpEF), obesity, type 2 diabetes mellitus, and weight management. These are the indications under study in its Phase 3 program. No approved use has been established, as the drug is still investigational.
Elecoglipron is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the Phase 3 clinical program evaluating the drug across nephrology, cardiology, and metabolic indications.
Elecoglipron is in Phase 3 clinical development. Five trials are active and recruiting, with no completed trials. The program includes randomized, double-blind, active-controlled studies. Elecoglipron is investigational and has not been approved by the FDA or any other regulatory agency.
Elecoglipron is being studied in five active Phase 3 trials. These include NCT07775404 in Asian participants with obesity or overweight, NCT07761117 in HFpEF or HFmrEF, NCT07753993 in chronic kidney disease, and NCT07667803, a master protocol in obesity or overweight with or without type 2 diabetes. All are currently recruiting.
Yes. Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, and Elecoglipron Test formulation 1 Dose B are alternative names referring to the same investigational drug, Elecoglipron. These names describe different formulation doses used in its clinical studies.